LB 10522

structure in first source

Also Known As:

7-(2-(2-aminothiazol-4-yl)-2-(a-carboxyl-3,4-dihydroxybenzyloxyimino)acetamide)-3-(3-(4-amino-1-pyrimidino)-1-propen-1-yl)-3-cephem-4-carboxylate; LB-10522; LB10522

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Lactams: 2198
    - beta-Lactams: 2386
      - Cephalosporins: 4007
        LB 10522: 1
- Sulfur Compounds: 278
  - Thiazines: 3
    - Cephalosporins: 4007
      - LB 10522: 1
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - beta-Lactams: 2386
      - Cephalosporins: 4007
        LB 10522: 1

Related Diseases

Infections

08/01/1996 - "Against Pseudomonas aeruginosa, LB10522 with a MIC at which 90% of the isolates are inhibited of 2 micrograms/ml was 16- and 32-fold more active than ceftazidime and ceftazidime against systemic infections caused by Staphylococcus aureus giorgio, Streptococcus pneumoniae III, Pseudomonas aeruginosa 1912E, Escherichia coli 851E, Proteus mirabilis 1315E, Serratia marcescens 1826E, and Acinetobacter calcoaceticus Ac-54. "

Related Drugs and Biologics

1.	Ceftazidime (Fortum)